Unknown

Dataset Information

0

Everolimus in the Treatment of Metastatic Breast Cancer.

ABSTRACT: The discovery of the mammalian target of rapamycin (mTOR) molecular pathway has brought insight into its vital role in breast cancer pathogenesis. Several clinical trials have shown that the mTOR inhibitor everolimus could improve patient outcomes in several subtypes of breast cancer, including hormone receptor-positive, human epidermal growth factor receptor-negative metastatic disease that has progressed after prior endocrine therapy. This review summarizes findings from clinical trials that have demonstrated the benefit of everolimus in metastatic breast cancer and highlights some new research directions utilizing everolimus.

SUBMITTER: Royce ME 

PROVIDER: S-EPMC4571987 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Everolimus in the Treatment of Metastatic Breast Cancer.

Royce Melanie E ME   Osman Diaa D  

Breast cancer : basic and clinical research 20150906

The discovery of the mammalian target of rapamycin (mTOR) molecular pathway has brought insight into its vital role in breast cancer pathogenesis. Several clinical trials have shown that the mTOR inhibitor everolimus could improve patient outcomes in several subtypes of breast cancer, including hormone receptor-positive, human epidermal growth factor receptor-negative metastatic disease that has progressed after prior endocrine therapy. This review summarizes findings from clinical trials that h  ...[more]

Similar Datasets

Unknown Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
| S-EPMC5519037 | biostudies-literature
Unknown Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer.
| S-EPMC7648338 | biostudies-literature
Unknown PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane.
| S-EPMC7519923 | biostudies-literature
Unknown Metastatic Renal Cancer: What Role for Everolimus?
| S-EPMC3998839 | biostudies-literature
Unknown Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
| S-EPMC7844919 | biostudies-literature
Unknown Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus.
| S-EPMC7959765 | biostudies-literature
Unknown Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report.
| S-EPMC5529768 | biostudies-other
Unknown Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer.
| S-EPMC4053575 | biostudies-literature
Unknown Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer.
| S-EPMC5214808 | biostudies-literature
Unknown Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma.
| S-EPMC5517440 | biostudies-other